The research specifically refers to the Novo Nordisk NovoPen 6 but I'll try to keep it general. #ATTD2021#dedoc°
The NovoPen has a five year battery which is impressive in comparison to the Medtronic InPen which only lasts 1 year and the battery cannot be replaced. #ATTD2021#dedoc°
The Smart Pen led to an improvement in glycaemic control. More time in range, less out of range, less variability. #ATTD2021#dedoc°
A big advantage of a Smart Pen over its non-Smart equivalent is the capture of doses and, as important, where doses were missed. #ATTD2021#dedoc°
Peter Adolfsson: Numbers can be high/low but not good/bad. No grading. #ATTD2021#dedoc°
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Advances in Closed Loop conclusions:
- A more aggressive target improves Time in Range (79% achievable) but does not increase Time Below Range
- Improvements, especially in younger adults when compared to open systems
- Closed Loop is safe. @ATTDconf#ATTD2021#dedoc°
Moreover, it is as safe for children as adults. #ATTD2021#dedoc°
Results not exclusive to Medtronic. Omnipod shows similar results in terms of improvements over open systems #ATTD2021#dedoc°
The next presentation I'm in is "Artificial intelligence (AI): Tangible Applications to Improve Diabetes Care". AI has come far in the last few years and the poster I mentioned yesterday shows how it can tailor closed loop systems. What else I wonder? @ATTDconf#ATTD2021#dedoc°
Stephane Bidet is saying with as little as 10 days of data, the AI can be trained effectively to smartly manage the user's BGLs. I believe it. Microsoft's Azure AI can effectively read forms with just 5 examples and images with 15 examples. #ATTD2021#dedoc°
Knowing the likely error in the predictions made, this variance is then used to ensure safe recommendations are made. This is smart. It will slightly hamper accuracy but ensure super-high or super-low BGLs do not happen. #ATTD2021#dedoc°
With Dexcom being at the forefront of pumps and CGMs I'm hoping for something special in this one. @ATTDconf#ATTD2021#dedoc°
Control IQ gave users 2.6 hours additional Time in Range over "Sensor Augmented Pumps" (open loop pump therapy) #ATTD2021#dedoc°
The number of people getting a Time in Range over 70% tripled with Control-IQ over the open loop therapy group. For long term complication management, this is a great result. #ATTD2021#dedoc°
Next is Medtronic talking about the outcomes for the first 4,000 users of the MiniMed 780G and the future for this commercial looping system. It will be interesting to see how it stacks up to the homegrown systems. @ATTDconf#ATTD2021#dedoc°
Dr Chantal Mathieu makes the point that the patient living with diabetes gets a few more hours with the disease than their health care team ;) #ATTD2021#dedoc°
Time in Range for the 780G was similar across the multiple countries involved in the analysis suggesting there was no bias from country-specific factors. #ATTD2021#dedoc°
First session at #ATTD2021. As a honeymooning T1D LADA who takes a GLP-1RA to help preserve my beta cells, I'm interested to see what's new with these "Great Little Peptides" #dedoc° @ATTDconf
The talk is about the oral version of Semaglutide which was also discussed at the EASD2020 conference last year. Many may be familiar with the injectable form which is sold under the name Ozempic. #dedoc° #ATTD2021